tiprankstipranks
Cannabix Technologies Inc (TSE:BLO)
:BLO
Want to see TSE:BLO full AI Analyst Report?

Cannabix Technologies (BLO) AI Stock Analysis

68 Followers

Top Page

TSE:BLO

Cannabix Technologies

(BLO)

Select Model
Select Model
Select Model
Neutral 41 (OpenAI - Gpt-5.6Sol)
Rating:41Neutral
Price Target:
C$0.39
▼(-23.14% Downside)
Action:Reiterated
Date:09/06/26
The score is driven primarily by weak financial performance—minimal revenue, ongoing losses, negative gross profit, and continued cash burn alongside equity depletion. Technicals add downside pressure with a price below key moving averages and negative MACD/weak RSI. Valuation is not supportive due to negative earnings and no dividend yield data.
Positive Factors
Low Financial Leverage
Modest debt reduces direct leverage pressure and limits interest-related strain compared with a highly indebted structure. This provides some financial flexibility if the company can improve commercialization, although the benefit is constrained by continuing losses and a shrinking equity base.
Negative Factors
No Meaningful Revenue Base
A persistently negligible revenue base indicates that the technology has not yet translated into meaningful commercial sales. Without recurring revenue, the company remains dependent on external funding and has limited ability to self-finance development, market expansion, or operating costs.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Financial Leverage
Modest debt reduces direct leverage pressure and limits interest-related strain compared with a highly indebted structure. This provides some financial flexibility if the company can improve commercialization, although the benefit is constrained by continuing losses and a shrinking equity base.
Read all positive factors

Cannabix Technologies (BLO) vs. iShares MSCI Canada ETF (EWC)

Cannabix Technologies Business Overview & Revenue Model

Company Description
Cannabix Technologies Inc., a technology company, develops marijuana and alcohol breathalyzer technologies for employers, law enforcement, workplaces, and laboratories in the United States. It offers Cannabix Marijuana Breath Test (MBT) for Tetrah...

Cannabix Technologies Financial Statement Overview

Summary
Income statement and cash flow are very weak: revenue has been effectively zero across recent years with persistent, widening net losses and negative gross profit. Cash flow remains consistently negative (ongoing cash burn), while the balance sheet benefit of modest debt is outweighed by significant equity erosion over time.
Income Statement
8
Very Negative
Balance Sheet
38
Negative
Cash Flow
18
Very Negative
BreakdownApr 2026Jul 2025Jul 2024Jul 2023Jul 2022
Income Statement
Total Revenue0.000.000.000.000.00
Gross Profit-172.97K-168.52K-153.24K-126.29K-29.22K
EBITDA-5.83M-4.55M-2.96M-2.01M-3.11M
Net Income-5.76M-4.69M-3.13M-2.14M-3.37M
Balance Sheet
Total Assets2.21M3.00M4.70M6.95M8.76M
Cash, Cash Equivalents and Short-Term Investments1.59M2.35M4.26M6.52M8.45M
Total Debt160.06K158.65K154.58K132.54K0.00
Total Liabilities431.71K447.71K248.02K237.17K120.84K
Stockholders Equity1.78M2.55M4.45M6.71M8.64M
Cash Flow
Free Cash Flow-1.74M-1.86M-2.11M-2.00M-2.13M
Operating Cash Flow-1.74M-1.84M-2.08M-1.97M-2.13M
Investing Cash Flow0.00-17.54K-30.96K-28.65K-4.59K
Financing Cash Flow968.26K-58.47K-143.53K10.88K492.50K

Cannabix Technologies Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.51
Price Trends
50DMA
0.52
Negative
100DMA
0.59
Negative
200DMA
0.60
Negative
Market Momentum
MACD
-0.03
Positive
RSI
29.05
Positive
STOCH
34.15
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:BLO, the sentiment is Negative. The current price of 0.51 is above the 20-day moving average (MA) of 0.47, below the 50-day MA of 0.52, and below the 200-day MA of 0.60, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 29.05 is Positive, neither overbought nor oversold. The STOCH value of 34.15 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:BLO.

Cannabix Technologies Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
50
Neutral
C$42.19M-2.17-303.05%35.27%58.34%
43
Neutral
C$17.36M-4.6278.25%89.06%37.62%
41
Neutral
C$50.37M-8.54-307.42%-84.43%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
TSE:BLO
Cannabix Technologies
0.41
-0.14
-25.45%
TSE:PINK
Perimeter Medical Imaging AI
0.28
0.03
12.24%
TSE:VPT
VentriPoint Diagnostics
0.09
-0.03
-21.74%

Cannabix Technologies Corporate Events

Business Operations and StrategyProduct-Related Announcements
Cannabix Expands BreathLogix Alcohol Monitoring Deployment in Montana
Positive
Aug 21, 2026
Cannabix Technologies has deployed its BreathLogix alcohol screening system at the Big Horn County Misdemeanor Probation and Pre-trial Services department in Montana, expanding its footprint under the state’s 24/7 Sobriety Program. The devic...
Business Operations and StrategyProduct-Related Announcements
Cannabix Targets Combat Sports for Marijuana Breath Test Rollout
Positive
Aug 5, 2026
Cannabix Technologies Inc., listed on the CSE, OTC and Frankfurt exchanges, develops marijuana and alcohol breath-testing technologies aimed at workplace and public safety markets. Its flagship Marijuana Breath Test targets recent THC use through ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Sep 06, 2026